跳转至内容
Merck
CN

SML3110

CRANAD-3

≥98% (HPLC)

别名:

(T-4)-[(1E,6E)-1,7-Bis[6-(diethylamino)-3-pyridinyl]-1,6-heptadiene-3,5-dionato-κO3,κO5]difluoroboron, CRANAD 3

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式(希尔记法):
C25H31BF2N4O2
化学文摘社编号:
分子量:
468.35
UNSPSC Code:
12352202
NACRES:
NA.77
Assay:
≥98% (HPLC)
Form:
powder
Quality level:
Storage condition:
desiccated
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助


Quality Level

assay

≥98% (HPLC)

form

powder

storage condition

desiccated

color

gray to black

solubility

DMSO: 2 mg/mL, clear (warmed)

storage temp.

2-8°C

SMILES string

FB(O1)(F)O=C(/C=C/C2=CN=C(N(CC)CC)C=C2)C=C1/C=C/C3=CC=C(N(CC)CC)N=C3

Biochem/physiol Actions

CRANAD-3, a curcumin analog, is a brain barrier penetrant smart NIRF (near-infrared) probe for both soluble and insoluble Aβ (amyloid beta) species in vivo. CRANAD-3 could be used to monitor the decrease in Aβs after drug treatment in transgenic AD (APP/PS1) mice. CRANAD-3 is suitable for in vivo dually-amplify signal via chemiluminescence resonance energy transfer (DAS-CRET) with ADLumin-1 a brain blood barrier penetrant smart chemiluminescence probe for Aβs
brain barrier penetrant smart NIRF probe for both soluble and insoluble Aβ (amyloid beta) species in vivo


存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable



历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库



Jing Yang et al.
Nature communications, 11(1), 4052-4052 (2020-08-15)
Turn-on fluorescence imaging is routinely studied; however, turn-on chemiluminescence has been rarely explored for in vivo imaging. Herein, we report the design and validation of chemiluminescence probe ADLumin-1 as a turn-on probe for amyloid beta (Aβ) species. Two-photon imaging indicates
Congping Chen et al.
ACS chemical neuroscience, 9(12), 3128-3136 (2018-08-02)
Abnormal deposition of brain amyloid is a major hallmark of Alzheimer's disease (AD). The toxic extracellular amyloid plaques originating from the aberrant aggregation of beta-amyloid (Aβ) protein are considered to be the major cause of clinical deficits such as memory
Xueli Zhang et al.
Proceedings of the National Academy of Sciences of the United States of America, 112(31), 9734-9739 (2015-07-23)
Near-infrared fluorescence (NIRF) molecular imaging has been widely applied to monitoring therapy of cancer and other diseases in preclinical studies; however, this technology has not been applied successfully to monitoring therapy for Alzheimer's disease (AD). Although several NIRF probes for



全球贸易项目编号

货号GTIN
SML3110-25MG04065267137223
SML3110-5MG04065267137230